Prevention of Bone Loss After Acute SCI by Zoledronic Acid

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

August 25, 2020

Study Completion Date

August 25, 2020

Conditions

Spinal Cord InjuryAcute Spinal Cord InjuryBone LossOsteoporosis

Interventions

DRUG

Zoledronic acid

Intravenous infusion of zoledronic acid 5 mg.

DRUG

Placebo

Placebo (saline) infusion to match zoledronic acid

Trial Locations (2)

Northwestern University Feinberg School of Medicine, Chicago

Rehabilitation Institute of Chicago, Chicago

All Listed Sponsors

collaborator

United States Department of Defense

FED

lead

Northwestern University

OTHER

NCT02325414 - Prevention of Bone Loss After Acute SCI by Zoledronic Acid | Biotech Hunter | Biotech Hunter